期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

Hp中性粒细胞激活蛋白研究进展 被引量：1

Progress in H.pylori neutrophil-activating protein
下载PDF
导出
摘要 幽门螺杆菌(Hp)是一种参与多种胃、十二指肠疾病的重要人类病原体,可引起慢性胃炎和消化性溃疡,并与胃癌密切相关。人类幽门螺杆菌感染的特征是胃黏膜炎症部位中性粒细胞持续浸润。幽门螺杆菌中性粒细胞激活蛋白(H.py-lorineutrophil-activating protein,HP-NAP)正是由于其能活化中性粒细胞而被如此命名。HP-NAP不仅是重要的毒力因子,而且是主要的候选疫苗抗原。本文综述了HP-NAP的结构、生物学活性和致病机制等的研究进展,并对其应用前景进行了展望。 Helicobacter pylorus is a major human pathogen associated with severe gastroduodenal diseases,including ulcers and cancers.Continuous recruitment of neutrophils into the inflamed gastric mucosal tissue is a hallmark of Helicobacter pylori infection in humans.An H.pylori protein that is highly immunogenic in humans and mice has been identified recently.This protein has been termed H.pylori neutrophil-activating protein(HP-NAP),due to its ability of activating neutrophils.HP-NAP is not only a bacterial virulence factor,but also a strong vaccine candidate.The research progresses of HP-NAP are reviewed,and their wide developmental prospects are also forecasted in this paper.
作者 高原 邹全明
机构地区 第三军医大学医学检验系临床微生物学及临床免疫学教研室
出处 《免疫学杂志》 CAS CSCD 北大核心 2006年第z1期64-67,72,共5页 Immunological Journal
基金 国家"863"项目(2003AA215020) 国家"十五"重大科技专项课题项目(2003AA2Z3C64)资助
关键词 幽门螺杆菌中性粒细胞激活蛋白 中性粒细胞:毒力因子 抗原 H.pylori neutrophil-activating protein Neutrophils Virulence factor Antigen
分类号 R392 [医药卫生—免疫学]
  • 相关文献

参考文献27

  • 1[1]Montecucco C,de Bernard M.Molecular and cellular mechanisms of action of the vacuolating cytotoxin (VacA) and neutrophil-activating protein (HP-NAP) virulence factors of Helicobacter pylori[J].Microbes Infect,2003,5 (8):715-721.
  • 2[2]Brisslert M,Enarsson K,Lundin S,et al.Helicobacter pylori induce neutrophil transendothelial migration:Role of the bacterial HP-NAP[J].FEMS Microbiol Lett,2005,249 (1):95-103.
  • 3[3]Baldari CT,Lanzavecchia A,Telford JL.Immune subversion by Helicobacter pylori[J].Trends Immunol,2005,26 (4):199-207.
  • 4[4]Nishioka H,Baesso I,Semenzato G,et al.The neutrophilactivating protein of Helicobacter pylori (HP-NAP) activates the MAPK pathway in human neutrophlls[ J].Eur J Immunol,2003,33 (4):840-849.
  • 5[5]Hamlet A,Thoreson AC,Nilsson O,et al.Duodenal Helicobacter pylori infection differs in cagA genotype between asymptomatic subjects and patients with duodenal ulcers[ J ].Gastroenterology,1999,116 (2):259-268.
  • 6[6]Evans DJ Jr,Evans,DG,Takemura T,et al.Characterization of a Helicobacter pylori neutrophil activating protein[ J].Infect Immun,2001,63 (63):2 213-2 220.
  • 7[7]Bylund J,Dahlgren C.Problems in identifying microbial-derived neutrophil activators,focusing on Helicobacter pylori[J].Trends Microbiol,2002,10 (1):12-14.
  • 8[8]Del Giudice G,Covacci A,Telford JL,et al.The design of vaccines against Helicobacter pylori and their development[J].Annu Rev Immunol,2001,19:523-563.
  • 9[9]Dundon W,Nishioka H,Montecucco C,et al.Problems in assaying neutrophil activators[ J ].Trends Microbiology,2001,9 (7):314-315.
  • 10[10]Ilari A,Stefanini S,Chiancone E,et al.The dodecameric ferritin from Listeria innocua contains a novel intersubunit iron-binding site[J].Nat Struct Biol,2000,7 (1):38-43.

二级参考文献15

  • 1[1]Gupta Rk, Rost BE, Relyveld E, et al. Vaccine design: the subunit and adjuvant approach [M]. New York: Plenum Press, 1995:229 - 248.
  • 2[2]Edelman R. Vaccine adjuvants[J]. Rev Infect Dis, 1980,2(3) :370-383.
  • 3[3]JensenOM, KochC. On the effect of Al( OH)3 as an immunological adjuvant[ J]. Acta Pathol Microbiol Immunol Scand,1988,96(3) :257 - 264.
  • 4[5]Harm HE. Mechanisms of stimulation of the immune response by aluminum adjuvants[J]. Vaccine, 2002,20 (16): S24-S39.
  • 5[6]Lee CK, Soike K, Giannasca P, et al. Immunization of rhesus monkeys with a mucosal prime, parenteral boost strategy protects against infection with Helicobacter pylori[J]. Vaccine, 1999,17(23 - 24): 3 072 - 3 082.
  • 6[7]Patricia LA, Donna F, Harry K, et al. Attenuated Salmonella enterica serovar Typhi expressing urease effectively immunizes mice against Helicobacter pylori challenge as part of a heterologous mucosal priming- parenteral boosting vaccination regimen[J]. Infect Immun, 2002,70(9): 5 096 - 5 106.
  • 7[8]Gottwein JM, Blanchard TG, Targoni OS, et al. Protective anti-Helicobacter immunity is induced with aluminum hydroxide or complete Freund' s adjuvant by systemic immunization[J]. J Infect Dis, 2001, 184(3): 308-314.
  • 8[9]Rossi G, Rossi M, Vitali CG, et al. A conventional beagle dog model for acute and chronic infection with Helicobacter pylori[J]. Infect Immun, 1999,67(6): 3 112-3 120.
  • 9[10]Malfertheiner P, Schultze V, Giudice GD, et al. Phase I safety and immunogenicity of a three- component H. pylori vaccine[J]. Gastroenterology, 2002,9 (22) : A-585.
  • 10李连奋.免疫佐剂的发展概况[J].微生物学免疫学进展,1997,25(2):57-61. 被引量：13

共引文献7

同被引文献14

引证文献1

免疫学杂志
2006年 第z1期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部